Dr. Qun Dai, MD

Dr. Dai practices at Staten Island University Hospital - North Campus in Staten Island, New York.

Dr. Dai's NPI, 1154313542, was assigned on August 22, 2005. Dr. Dai holds New York license 218079.

Dr. Dai's primary practice is Staten Island University Hospital - North Campus, at 475 Seaview Ave, Staten Island, NY 10305 in Richmond County. The practice phone is (718) 226-4502.

Dr. Dai's primary practice is Staten Island University Hospital - North Campus in Staten Island, New York. Dr. Dai is also affiliated with Staten Island University Hospital. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Dai to 1 more hospital, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dai practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dai is board certified in hematology by the American Board of Internal Medicine. Dr. Dai is licensed in New York.

CMS data shows 1,193 Medicare services from Dr. Dai across 10 procedure codes in 2024, for 427 Medicare patients. Medicare paid $88,067 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 427 Medicare patients who saw Dr. Dai in 2024. The largest group is 75 to 84, with 169 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dai's median patient age at 74, with 84% women.

In 2024, Dr. Dai wrote 771 Medicare Part D claims for 233 patients. 76% of them were for generic drugs. CMS names the drug for 608 of them, across 19 drugs with 11 or more claims each, at $1,488,460 in total drug cost. In 2023, CMS named 506 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Dai for performance year 2024, reported as part of a group. Dr. Dai accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 25 papers to Dr. Dai, published from 2010 to 2025. 2014 was the busiest year, with 3. The most frequent topics are Cell Line, Tumor, Biomarkers, Tumor and Cell Membrane. Dr. Dai has published most often in Mol Biotechnol. Dr. Dai's most frequent co-authors are Muhammad Jawad Popalzai, Weijing Sun, MD and Homam Alkaied, MD.

Dmand AI links Dr. Dai to 4 clinical trials, 4 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Carcinoma In Situ, Breast Neoplasms and Carcinoma, Intraductal, Noninfiltrating. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 11 general payments to Dr. Dai from 8 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 87% of the total. Incyte Corporation paid the most, $2,818.